FIP guidelines offer hope for quick diagnosisSeptember 30, 2022The 2022 AAFP/EveryCat Feline Infectious Peritonitis Diagnosis Guidelines detail characteristics and pathogenesis of feline infectious peritonitis (FIP), a fatal but difficult-to-detect disease caused by feline coronavirus (FCoV).
SPONSORED CONTENTYour Parasite Protection Recommendation, SimplifiedManaging parasite prevention doesn’t have to be complicated. Discover a single solution that protects against multiple threats. + Learn More
Is an FIP treatment close at hand?March 5, 2020Considered fatal, feline infectious peritonitis (FIP) is now being called “treatable” by Niels Pedersen, DVM, PhD, who has studied the disease for nearly the entirety of his career.
FIP treatment in the worksDecember 2, 2019A vaccine that could save the lives of countless domestic cats is being developed at Colorado State University (CSU).
KSU veterinary researchers, Anivive license FIP antiviral drugSeptember 20, 2018A collaboration at Kansas State University and Anivive Lifesciences is promoting the commercial development of GC376, an antiviral compound for feline infectious peritonitis (FIP), which previously has had no effective treatment or cure. Yunjeong Kim, DVM, PhD, ACVM, and Kyeong-Ok "KC" Chang, DVM, MS, PhD, virologists at KSU's College of Veterinary Medicine, and William Groutas, a medicinal chemist at Wichita State University, have been collaborating since 2006 to develop antiviral drugs for human and animal viruses. The licensing agreement was coordinated by the KSU Institute for Commercialization with Anivive Lifesciences, a California company whose proprietary software accelerates the discovery and development process of new pet medicines. "We have been working on antiviral drugs that inhibit a specific virus protease of some important human and animal viruses, and we were able to make very potent inhibitors of FIP," Dr. Kim said. "Through collaborative work with Niels Pedersen at the University of California, Davis—including a field trial on feline patients—we became increasingly hopeful that antiviral treatment may one day substantially benefit cats with FIP. Licensing our compound to Anivive Lifesciences is a huge step forward in transitioning our research to commercialization to make this treatment available to the …
